[Progression of Chronic Heart Failure: Prognostic Criteria and Non-Drug Prevention]

E R Kurlyanskaya1, T L Denisevich1, A G Mrochek1

  • 1Republic Scientific and Practical Center "Cardiology", Minsk.

Kardiologiia
|April 20, 2019
PubMed

Insights

This study developed risk models and non-drug prevention strategies to reduce chronic heart failure (CHF) progression. Applying these interventions significantly lowered CHF severity class increases from 11.7% to 2.2%.

Area of Science:

  • Cardiology
  • Public Health

Background:

  • Chronic heart failure (CHF) is a progressive condition requiring effective management strategies.
  • Understanding the frequency and risk factors for CHF progression is crucial for developing targeted interventions.

Purpose of the Study:

  • To determine the frequency of chronic heart failure (CHF) progression over 24 months.
  • To develop multifactorial risk models for CHF progression.
  • To establish non-drug secondary prevention measures for CHF.

Main Methods:

  • A cohort of 531 patients with functional class (FC) I-III CHF was studied.
  • Clinical, instrumental, and laboratory investigations, including NT-proBNP, were performed.
  • Patient data was collected using AUDIT and Morisky Green questionnaires.

Main Results:

  • The 24-month CHF progression rate was 11.7%. Key progression factors included myocardial infarction history and low treatment adherence.
  • Specific risk factors for FC I to II progression were identified (e.g., age >74, obesity, hypertension, alcohol intake).
  • Multifactorial risk models demonstrated high prognostic accuracy (86.3% for FC I, 85.5% for FC II). A non-drug prevention program reduced progression to 2.2% in high-risk patients.

Conclusions:

  • The combined use of risk assessment scores and a non-drug prevention program effectively reduced CHF severity class progression.
  • This approach lowered the frequency of CHF class increases from 11.7% to 2.2%.
Abstract

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
862
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.3K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
824
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.0K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
822
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.2K